CJC-1295 (no DAC)vsHexarelin

CJC-1295 (no DAC), also known as Mod GRF 1-29, is a synthetic analogue of the first 29 amino acids of growth hormone-releasing hormone (GHRH). Four amino acid substitutions (at positions 2, 8, 15, and 27) have been made to increase resistance to enzymatic degradation while preserving full biological activity at the GHRH receptor (GHRH-R), a G protein-coupled receptor expressed on somatotroph cells in the anterior pituitary.

When CJC-1295 binds the GHRH receptor, it activates the Gs alpha subunit, which stimulates adenylyl cyclase to produce cyclic AMP (cAMP). Rising cAMP levels activate protein kinase A (PKA), which phosphorylates CREB (cAMP response element-binding protein) and other transcription factors that drive GH gene expression and secretion. Importantly, this mechanism preserves the natural pulsatile pattern of GH release because it works within the existing hypothalamic-pituitary feedback loop — somatostatin still provides inhibitory regulation between pulses.

The key advantage of the no-DAC version over the DAC version is this preservation of pulsatility. Because its half-life is approximately 30 minutes, it produces a discrete GH pulse that rises and falls naturally, mimicking the body's own secretory pattern. This pulsatile pattern is believed to be physiologically superior to sustained elevation because GH receptor sensitivity is maintained between pulses, and the liver's IGF-1 production response is optimized by intermittent rather than continuous GH stimulation. This is why CJC-1295 (no DAC) is often preferred by practitioners despite requiring more frequent dosing.

Hexarelin is a synthetic hexapeptide (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH2) that acts as one of the most potent agonists of the growth hormone secretagogue receptor (GHS-R1a). Its strong receptor affinity produces the highest GH release amplitude among the GHRP family, but this potency comes with broader neuroendocrine activation compared to more selective agents like ipamorelin.

At the pituitary level, hexarelin binding to GHS-R1a activates Gq/11-coupled phospholipase C, generating IP3 and DAG. IP3-mediated calcium release from intracellular stores triggers massive GH vesicle exocytosis. The strong GH response also comes with significant stimulation of cortisol (via ACTH release from corticotrophs) and prolactin release from lactotrophs — side effects that limit its clinical utility compared to more selective secretagogues.

Uniquely among GHRPs, hexarelin demonstrates significant cardioprotective properties independent of GH release. GHS-R1a receptors are expressed on cardiomyocytes, and hexarelin binding activates survival signaling through the PI3K/Akt and ERK1/2 pathways, protecting cardiac cells from ischemia-reperfusion injury and apoptosis. Hexarelin also binds to the scavenger receptor CD36 on macrophages and cardiac tissue, which may contribute to its anti-atherosclerotic and cardioprotective effects. Animal studies have demonstrated reduced infarct size and improved cardiac function following hexarelin administration. However, a significant practical limitation is desensitization — continuous hexarelin use leads to progressive reduction in GH response within 2-4 weeks, necessitating cycling protocols to maintain effectiveness.